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Abstract
 
Glutamic acid decarboxylase (GAD)65 is an early and important antigen in both human diabetes
mellitus and the nonobese diabetic (NOD) mouse. However, the exact role of GAD65-specific
T cells in diabetes pathogenesis is unclear. T cell responses to GAD65 occur early in diabetes
pathogenesis, yet only one GAD65-specific T cell clone of many identified can transfer diabetes.
We have generated transgenic mice on the NOD background expressing a T cell receptor
(TCR)-specific for peptide epitope 286–300 (p286) of GAD65. These mice have GAD65-
specific CD4
 
 
 
 T cells, as shown by staining with an I-A
 
g7
 
(p286) tetramer reagent. Lymphocytes
from these TCR transgenic mice proliferate and make interferon 
 
 
 
, interleukin (IL)-2, tumor
necrosis factor (TNF)-
 
 
 
, and IL-10 when stimulated in vitro with GAD65 peptide 286–300, yet
these TCR transgenic animals do not spontaneously develop diabetes, and insulitis is virtually
undetectable. Furthermore, in vitro activated CD4 T cells from GAD 286 TCR transgenic
mice express higher levels of CTL-associated antigen (CTLA)-4 than nontransgenic littermates.
CD4
 
 
 
 T cells, or p286-tetramer
 
 
 
CD4
 
 
 
 Tcells, from GAD65 286–300-specific TCR transgenic
mice delay diabetes induced in NOD.
 
scid
 
 mice by diabetic NOD spleen cells. This data suggests that
GAD65 peptide 286–300-specific T cells have disease protective capacity and are not pathogenic.
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Introduction
 
Type I diabetes mellitus is an autoimmune disease in which
lymphocytes infiltrate the pancreatic islets and destroy the
insulin-producing 
 
 
 
 cells (1). Nonobese diabetic (NOD)
 
*
 
mice develop a similar destructive pancreatic infiltrate
which results in diabetes (2). NOD mice also develop
lymphocytic infiltrates in other organs such as salivary glands
and thyroid, which parallel other autoimmune syndromes
that develop in some humans with diabetes. T cells are
central to diabetes pathogenesis, as evidenced by the ability
of purified CD4 and CD8 T cells to cause diabetes upon
adoptive transfer (3, 4).
In NOD mice, insulitis is first observed at 3–8 wk of age,
but overt diabetes does not occur until 12–25 wk of age (5).
Humans with type I diabetes also have a lag between onset
of autoimmunity and overt diabetes; autoreactive T cell and
antibody responses can precede clinical diabetes, sometimes
by years (6). A regulatory cell type present early, but which
disappears or becomes ineffective as the disease progresses,
may be responsible for the delay of diabetes initiation.
Transfer studies show that CD4
 
 
 
 T cells from young predi-
abetic mice can delay the transfer of diabetes to irradiated
adult NOD mice by spleen cells from recently diabetic
mice (7). Many different cell types may regulate diabetes
pathogenesis. For example, NOD mice have lower levels of
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 BCG, bacillus Calmette-Guerin;
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acid decarboxylase; MFI, mean fluorescence intensity NOD, nonobese
diabetic; p286, peptide 286-300 of GAD65; G286, mice expressing p286-
specific TCR-
 
 
 
 and -
 
  
 
transgenes. 
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CD4
 
 
 
CD25
 
 
 
 cells, and increasing the number of these cells
delays diabetes onset (8, 9) (unpublished data). A shift from
production of Th1 cytokines to Th2 cytokines is also protec-
tive in diabetes models (10). Another CD4
 
 
 
 subset identified
in mice and humans, named Tr1, makes IFN-
 
 
 
 and IL-10,
but not IL-4, and can downregulate immune responses (11).
In some situations, even IFN-
 
 
 
–producing cells may have a
regulatory role in diabetes development. This is suggested by
the ability of IFN-
 
 
 
 deficient (but not IL-10 or IL-4 deficient)
NOD mice to develop diabetes after treatment with bacillus
Calmette-Guerin (BCG), an immune stimulant which nor-
mally prevents diabetes development (12). The relative im-
portance of the different regulatory populations in maintaining
tolerance to islet antigens has not been determined.
Studies using mice transgenic for different TCRs show
that even a restricted TCR repertoire can lead to develop-
ment of diabetes. For example, expression of nondisease-
related TCR-
 
 
 
 and -
 
 
 
 chains in NOD mice does not
reduce diabetes incidence (13). Similarly, NOD mice ex-
pressing a MHC class I–restricted, LCMV-specific TCR
develop diabetes as long as endogenous TCRs can still re-
arrange (14). This suggests that the limited diverse reper-
toire, most likely the result of endogenous TCR-
 
 
 
 chains
pairing with the transgenic 
 
 
 
 chain, generates sufficient
self-reactive, pathogenic T cell responses to result in diabe-
tes. Mice expressing TCR transgenes specific for unidenti-
fied 
 
 
 
 cell antigens show that even a single specificity can
generate a T cell response adequate for disease progression.
Mice expressing the BDC2.5 TCR, derived from a diabe-
togenic CD4
 
 
 
 clone isolated from NOD spleen, develop
insulitis and diabetes (15, 16). Likewise, mice expressing
the 4.1 TCR, which uses a TCR isolated from a CD4
 
 
 
 T
cell clone found in the islets of a diabetic NOD mouse,
rapidly develops diabetes in 75% of female mice (17). Stud-
ies with these two TCR transgenics have been instrumen-
tal in defining many aspects of diabetes pathogenesis (5).
However, these studies are limited by the unknown anti-
gen specificity of these transgenic TCRs.
Two of the most important autoantigens in diabetes
pathogenesis, in both mice and humans, are insulin and
glutamic acid decarboxylase (GAD)65 (18, 19). The pres-
ence of antibodies specific for these two antigens is predic-
tive of future diabetes onset in individuals with a permissive
HLA type and a family history of diabetes (20). Insulin is
the major secreted protein of the 
 
 
 
 cell and is also ex-
pressed in the thymus. Both CD4
 
 
 
 T cell clones specific
for the insulin immunodominant epitope B(9–23), and
CD8
 
 
 
 cells specific for an overlapping epitope, B (15–23),
can induce diabetes upon adoptive transfer (21, 22).
GAD65, the enzyme which makes the inhibitory neu-
rotransmitter GABA from glutamic acid, is expressed only
in islet cells and the brain (23). Both antibody and T cell
responses to GAD65 occur at the earliest detectable stages
of diabetes pathogenesis in mice and humans (24–26), lead-
ing to speculation that GAD65 may be the first antigen for
which tolerance is broken. As with insulin, inducing toler-
ance to GAD65 by injecting GAD65 or its peptide epitopes
can prevent diabetes (27, 28). Furthermore, diabetes did
not develop in mice in which GAD65 expression in the is-
lets was ablated by expression of GAD anti-sense RNA un-
der the insulin promoter. (29). Despite this evidence, only
one diabetogenic GAD-specific clone has been identified
(30). Clearly much is still unknown about the role of
GAD65-specific T cells in diabetes pathogenesis.
The goal of this study is to determine the role of T cells spe-
cific for one GAD65 epitope, peptide 286–300 (p286), in the
pathogenesis of diabetes in NOD mice. p286 is one of three
immunodominant epitopes of GAD65 previously identified
by this laboratory by screening T cell hybridomas derived
from 10–12-wk-old NOD mice immunized with GAD65
protein emulsified in IFA (31, 32). T cells specific for this re-
gion of GAD65 (p286 in one case, peptide 290–309 in an-
other) were also isolated in two separate systems from the
spleens of unimmunized NOD mice, confirming the presence
of these T cells in unmanipulated mice (unpublished data)
(10). We have developed and characterized NOD mice ex-
pressing a p286-specific TCR transgene, and found that these
mice do not develop diabetes. Our results suggest instead, that
GAD65-p286-specific T cells may play a protective role in the
development of diabetes in NOD mice.
 
Materials and Methods
 
Cloning of 286-specific TCRs into TCR-
 
 
 
 and -
 
 
 
 Expression Vec-
tors.
 
RT-PCR using primer pairs specific for each V
 
 
 
 and V
 
 
 
was used to determine that B16.3, a p286-specific hybridoma, ex-
presses V
 
 
 
4.5-J
 
 
 
6 and V
 
 
 
1-J
 
 
 
2.7 (unpublished data). To clone
this TCR, PCR was performed on genomic DNA preparations
from B16.3. Primers were designed at the beginning of the leader
segment of V, and the second primer located in the intron 
 
 
 
200-
bp downstream of the J segment for both 
 
 
 
 and 
 
 
 
 chains. Primer
sequences were designed to engineer restriction sites (underlined)
for subcloning as follows: 
 
 
 
 chain forward, CCGTCTGGAGTC-
GACTTCCACCATGAGC; 
 
 
 
 chain reverse, CTGGTCTAC-
CCGCGGCTACTCCAGGGACCCAGGAATTTG; 
 
 
 
 chain
forward, TCTCACTGCCTAGCCATGAACACTTCTCCAGC-
TTTA; 
 
 
 
 chain reverse, AACCTCGGTGCGGCCGCTTTGGA-
TATTTGTCCTTTG. The 
 
 
 
 chain PCR product was subjected
to an additional round of PCR with a second forward primer, TG-
CAGAACCCGGGCTTCTCACTGCCTAGCCATG, coupled
with the 
 
 
 
 chain reverse primer to introduce the XmaI site. Once
the V(D)J sequence was confirmed, the insert was digested with
XmaI and NotI (
 
 
 
) or XhoI and SacII (
 
 
 
) and then subcloned into
previously described expression vectors containing TCR regulatory
and constant regions (pT
 
 
 
cass, pT
 
 
 
cass; reference 33).
 
Generation of Mice Expressing p286-specific TCR-
 
  
 
and -
 
 
 
 Trans-
genic Mice.
 
The TCR-
 
 
 
 and -
 
 
 
 chain vectors were cut with SalI
and KpnI respectively to remove prokaryotic sequences. The puri-
fied 18-kb (TCR-
 
 
 
) and 17-kb (TCR-
 
 
 
) linearized vectors were
then injected into NOD embryos. The DNA was injected into
NOD embryos (instead of NOD
 
 
 
FVB F1 embryos) to avoid po-
tentially introducing diabetes protective loci from the FVB strain
linked to the site of transgene integration.
Potential founders were screened for integration of the trans-
genes by PCR using the same primers described above. Expression
of 
 
  
 
 pairs was confirmed by staining with I-A
 
g7
 
/p286 tetramers.
Two lines were established (A and B). Unless otherwise indicated,
all data shown here were obtained using A line mice. These TCR
transgenic mice expressing p286-specific TCR-
 
 
 
 and -
 
 
 
 trans- 
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genes will be subsequently referred to as G286 (GAD65–286–300).
All animal studies have been approved by Stanford University’s
Administrative Panel for Laboratory Animal Care (A-PLAC).
 
Cell Isolation.
 
Where indicated, pooled lymph nodes, specific
lymph nodes, or spleen cells were macerated and washed in
RPMI 1640 media containing 200 U/ml penicillin, 200 
 
 
 
g/ml
streptomycin, 10 mM Hepes, 0.06 
 
 
 
g/ml 
 
L
 
-glutamine, 10
 
 
 
5
 
 mM
2-ME, and 10% FCS. For spleen cells, red blood cells were lysed
by incubation in ACK lysing buffer (0.15 M NH
 
4
 
Cl, 1
mMKHCO
 
3
 
, 0.1 mM Na
 
2
 
EDTA; reference 34), 4 ml/spleen for
4 min, then washed in media. Where indicated, CD4
 
 
 
 T cells
were purified by negative selection using magnetic beads conju-
gated with CD8 and B220 antibodies (Dynal).
 
Flow Cytometry.
 
The following antibodies were used for
FACS
 
®
 
 analysis: anti-CD4 (RM4–5) and anti-CD8 (5H-10);
FITC and PE conjugated, were purchased from Caltag Laborato-
ries. Antibodies against CD4 (GK1.5) and CD8 (53–6.7) conju-
gated to Texas Red and APC were obtained from the laboratory of
Irving Weissman. Antibodies against the following V
 
 
 
8 (MR5–2),
CD3 (145–2C11), CD25 (7D4), CD44 (IM7), CD62L (MEL-14),
CD69 (H1.2F3), all FITC conjugated; V
 
 
 
2-PE (B20.1) CTL-asso-
ciated antigen (CTLA)-4-PE (UC10–4F10–11) were all purchased
from BD PharMingen. All washes and staining were performed in
PBS with 1% FBS. All staining was done at 4
 
 
 
 for 30 min following
standard protocols (BD PharMingen).
To stain p286-specific T cells, a tetramer was assembled by as-
sociating streptavidin-PE or streptavidin-APC with soluble bio-
tinylated I-A
 
g7
 
 monomers to which GAD peptide 286–300 was
covalently linked. The soluble monomers were produced by Luc
Teyton (Scripps Research Institute, La Jolla, CA) and synthesized
as indicated previously (35). Any staining which included p286-
specific tetramer was done at room temperature for 45 min.
For assessment of CTLA-4 expression, pooled lymph node
cells from G286 mice and littermate transgene negative mice were
activated in vitro with plate-bound anti-CD3 (2 
 
 
 
g/ml) and anti-
CD28 (4 
 
 
 
g/ml). Cells were harvested after 48 h and stained with
CD4-FITC and p286-tetramer. Cells were then fixed for 20 min
in 2% formaldehyde and permeabilized with 0.5% saponin. Anti–
CTLA-4 was added for 30 min at room temperature.
 
Histological Analysis.
 
Pancreas or salivary gland tissue was
fixed in 10% formalin and paraffin-embedded sections were
stained with H&E. Tissue cuts were made 100 microns apart to
avoid counting any islets twice. Insulitis was assessed for each is-
let, and scored as: no insulitis, periinsulitis, and intrainsulitis.
 
Proliferation and Cytokine Detection.
 
To activate cells in vitro,
2.5 
 
 
 
 10
 
5
 
 pooled lymph node or spleen cells from G286 and non-
transgenic mice were activated in triplicate with the indicated dose
of GAD65 p286 and 2.5 
 
 
 
 10
 
5
 
 irradiated (3,000 rads) NOD spleen
cells (alterations to this protocol are indicated). Proliferation was as-
sessed by 
 
3
 
[H]thymidine incorporation. 0.5 
 
 
 
Ci/well 
 
3
 
[H]thymi-
dine was added at 72 h, and plates were harvested 12 h later unless
otherwise indicated. To determine expression of IL-2, IL-4, IL-5,
TNF-
 
 
 
, and IFN-
 
 
 
, antibody pairs from BD PharMingen were
used, and a sandwich immunoassay was performed following stan-
dard protocols with supernatants from in vitro activated cultures.
Streptavidin-Europium was used to quantitate the amount of
bound biotinylated secondary antibody. IL-10 ELISAs were per-
formed with precoated plates and reagents from Endogen. The cul-
tures used to determine IL-10 expression contained 6 
 
  
 
10
 
5
 
 lymph
node cells plus 6 
 
  
 
10
 
5
 
 irradiated NOD spleen cells.
 
Cell Transfer Studies and Monitoring of Diabetes.
 
2–10 
 
 
 
 10
 
6
 
unfractionated spleen cells from newly diabetic NOD mice were
injected intravenously (tail vein) into 5–10-wk-old female NOD
 
scid
 
 mice. As indicated for each experiment, various lymphocyte
populations from G286 mice were mixed with these spleen cells.
All G286 mice used as donors were female. When indicated,
spleen or lymph node cells from G286 mice were activated with
anti-CD3 (2 
 
 
 
g/ml) and anti-CD28 (4 
 
 
 
g/ml) or with 10 
 
 
 
g/ml
p286 for 48 h. The final volume of all injections was 100  l per
mouse in PBS/0.1% BSA. Urine glucose levels were monitored
using Chemstrips (Roche Laboratories) which have a glucose
threshold of 100 mg/dL. Mice were considered diabetic on the
first of three consecutive high glucose readings and were killed
after the third high reading.
Statistical Analysis. Statistical significance of delay in diabetes
transfer was determined at each time point by Fisher’s exact test
and is indicated on the incidence plots. All comparisons are be-
tween the experimental condition indicated and the control con-
dition consisting of spleen cells from diabetic NOD females trans-
ferred alone, except in Fig. 6 A where samples containing
tetramer positive cells are compared with those containing tet-
ramer-negative cells. P values   0.05 are indicated by the symbol *,
whereas P values  0.01 are indicated by the symbol #.
Results
Generation of TCR Transgenic Mice Specific for Peptide
Epitope 286–300 of GAD65.  To study the function of
GAD65-specific T cells in NOD mice, TCR transgenic
mice were produced with TCR-  and -  chains cloned
from a hybridoma (B16.3) expressing a TCR specific for
p286. This transgenic line will subsequently be referred to
as G286. B16.3 expresses one functional TCR-  (V 4.5-
J 6) and TCR-  (V 1-J 2.7) rearrangement. The TCR- 
and -  variable region sequences were cloned by genomic
PCR, and the   and   chains were then ligated into sepa-
rate TCR expression vectors containing the constant re-
gion and regulatory elements necessary for normal T cell–
restricted TCR expression (33).
Incorporation and expression of the transgene was as-
sessed by genomic PCR and flow cytometry, respectively.
Transgenic TCR-  and -  specific primers amplify PCR
product from genomic DNA isolated from transgene-posi-
tive but not transgene-negative littermates (Fig. 1 A). Be-
cause a V 1-specific antibody is not available, expression of
the TCR-  chain transgene was determined by a lack of ex-
pression of other V  proteins due to allelic exclusion. In
NOD mice, the normal expression of CD4  V 8  cells is
8–12% of peripheral blood lymphocytes, but in G286 mice,
the percentage of CD4 V 8  cells is  0.5% of PBLs (Fig. 1
B). V 5 staining gave similar results (unpublished data). This
suggests that 90–95% of the T cells express the transgenic  
chain. The   chain of this TCR is V 4.5, for which there
also is not a specific antibody. Because allelic exclusion is not
as complete for TCR-  chain, one cannot assess expression
of the TCR-  transcript using this same approach.
To assess   chain expression and determine the expression
level of p286-specific TCR in G286 mice, a tetramer re-
agent containing a soluble biotinylated I-Ag7 molecule with
covalently linked p286 was employed (35). This soluble
I-Ag7/p286 molecule was then conjugated to streptavidin-PE.
T cells from G286 mice stain specifically with p286-tet-484 Glutamic Acid Decarboxylase 65–specific T Cells Delay Diabetes Transfer
ramer, as compared with the OVA-specific tetramer control,
and  0.5% of CD4  T cells from nontransgenic NOD mice
stain with the p286-specific tetramer (Fig. 1 C). 10–20% of
CD4  and 40% of CD8  T cells are positive for p286-tet-
ramer staining. The percentage of CD4  cells that are tet-
ramer positive increases when T cells from G286 mice are
activated with p286 and NOD APCs (Fig. 6 C, left).
Lymphocyte Populations in G286 Mice Are Normal. Lym-
phocyte populations in G286 mice and nontransgenic NOD
littermates were compared. The total percentage of acti-
vated cells in peripheral lymphoid organs was similar in the
transgenic and littermate controls, as determined by expres-
sion of CD69, CD25, and CD62L (unpublished data). In
G286 mice however, a slightly higher percentage of
CD4 tetramer  cells displayed an activated phenotype (as
indicated by expression of CD25 and CD44) when com-
pared with CD4 tetramer  cells (unpublished data). In con-
trast to many MHC class II–restricted TCR transgenics,
which have a skewing of CD4:CD8 ratios in the thymus
and in the periphery (36), little or no skewing in the CD4:
CD8 ratio was observed in lymph node, spleen, or thymus
of G286 mice when compared with NOD littermates (Fig.
1 D and unpublished data).
Endogenous TCR-  Chain Expression Is Necessary for Selec-
tion of CD4 T Cells in G286 Mice. G286 mice were
crossed onto NOD TCR C  /  mice to determine the
role of T cells expressing endogenous TCR-  chain in se-
lection and disease. In MHC class II–restricted TCR trans-
genics crossed onto C  / , one would expect CD4  cells
to increase and CD8  cells to decrease due to a decrease in
the endogenous repertoire. Surprisingly, fewer CD4  T
cells were found in the periphery, and the percentage of
CD8  cells was not diminished in G286 C  /  mice. The
lack of V 2  cells confirms that these mice lack expression
of endogenous   chains and are TCR-C  / . Many (20%)
of the CD4  cells from G286 C  /  mice express V 8,
indicating that allelic exclusion of V  is not complete (Fig.
2 A). The most likely explanation for this result is that en-
dogenous TCR-  chain expression in G286 C  /  NOD
mice allows this autoreactive T cell to survive thymic nega-
tive selection; the few CD4  cells in G286 C  /  NOD
mice are compensating by rearranging endogenous V 
genes. Coexpression of an endogenous TCR-  chain
paired with a transgenic TCR-  chain may allow for suffi-
cient downregulation of the transgenic autoreactive TCR
to allow escape from thymic negative selection without
failure to be positively selected. This phenomenon has
been observed with other autoreactive TCRs (37).
Expression of one specific TCR in comparison to total
TCR can be assessed by comparing TCR-specific staining
(with a tetramer or clonotypic antibody) with the total
TCR expression level (represented by CD3 expression;
reference 38). Cells for which the majority of the surface
TCR is p286-specific will lie on the diagonal of CD3 and
tetramer staining. For thymic and lymph node CD8  cells
from G286 mice, the majority of tetramer-staining cells are
in this diagonal gate (Fig. 2 B). This unusual CD8  popula-
tion binds I-Ag7/p286 tetramer and therefore, is restricted
by a MHC class II molecule. Without the help of CD4
binding, these CD8  cells are likely to have a lower affinity
TCR-MHC/peptide interaction, and may thus allow
CD8  T cells with a higher expression of p286-specific
TCR to survive negative selection.
For CD4  cells, the majority of lymph node tetramer-
staining cells have lower tetramer staining without a reduc-
tion in CD3 staining, indicating that significant levels of
other TCRs are expressed on the surface of most of the
p286-specific CD4  cells. However, a minority of CD4 
cells from G286 mice express high levels of p286-specific
TCR without other TCRs, as indicated by cells in the di-
agonal gate. It is not clear how these cells survive selection,
Figure 1. Characterization of G286 mice. (A) Integration of TCR-V 
and -V  constructs is shown by genomic PCR. (Left) DNA amplified
with TCR-  specific primers from transgene positive (lane 1) and
transgene negative (lane 2) mice. (Right) DNA amplified with TCR- 
specific primers from transgene positive (lanes 3 and 4) and transgene
negative (lane 5) mice. (B) Staining of peripheral blood lymphocytes
with antibodies against V 8 (x axis) and CD4 (y axis) for NOD litter-
mate (left) and transgene positive (right). (C) Staining of spleen cells from
NOD (top) or G286 mice (bottom) with I-Ag7-286 tetramer and CD4 or
CD8 (right). As a control, cells were also stained with an I-Ag7 tetramer
containing peptide 323–339 of OVA (left).   (D) Thymocytes from NOD
(left) or G286 (right) mice were stained with antibodies against CD4 and
CD8. The percentage of cells in different boxed gates are shown.485 Tarbell et al.
but a similar result has been seen with another self-specific
TCR (39). It is interesting to note that the percentage of
CD4  cells, which only express a p286-specific TCR (in
the diagonal gate), is lower in the lymph node as compared
with the thymus; this may be a result of peripheral toler-
ance mechanisms. Because G286 C  /  mice have very
few CD4  T cells, all subsequent experiments were per-
formed with C  /  or C  /  mice.
NOD Mice Expressing the p286-specific TCR Transgenes
Do Not Develop Diabetes. G286 females and transgene
negative littermates were followed for 30 wk for diabetes.
80% of the nontransgenic and 0% of the G286 mice devel-
oped diabetes (Fig. 3 A). At 30 wk, the six G286 mice and
two remaining nondiabetic nontransgenic mice were killed
and insulitis assessed. Only 10% of islets in transgenic mice
displayed any insulitis, whereas both of the nontransgenics
had severe insulitis in the few islets that remained. A similar
pattern of insulitis was seen in 17-wk-old mice (Fig. 3 B).
Subsequently, none of the dozens of G286 mice used for
other experiments have developed diabetes, and the second
G286 transgenic B line also does not develop diabetes. Be-
cause mice which express an unrelated transgenic TCR can
still develop diabetes (13, 14), and because G286 mice do
not develop diabetes, it is likely that the p286-specific
TCR plays a protective role in diabetes pathogenesis. In
addition, both NOD and G286 mice develop lymphocytic
infiltration in the salivary glands, although sialtis in G286
mice is less severe (Fig. 3 C). This suggests that the lack of
inflammatory infiltration in the pancreas of G286 mice may
be due to specific suppression of islet-specific responses and
not due to the absence of a pathogenic repertoire or to a
general immune disregulation. 
Cyclophosphamide (CY) treatment of NOD mice ac-
celerates diabetes onset (40). G286 mice and littermate
controls were treated with (CY) at 8 and 10 wk of age.
Within 17 d after the second CY injection, 11/11 non-
transgenic littermate mice and 0/10 of G286 mice were
diabetic. The transgenic mice were followed for 40 d
and never developed diabetes. At this time point, five of
the transgenic mice were assayed for insulitis, and one
mouse tested positive (unpublished data).
Transgenic T Cells Proliferate and Produce Cytokines In Re-
sponse to p286 In Vitro. To show that T cells from G286
mice were functional and not tolerant to peptide stimu-
lation, lymph node and spleen cells were isolated and
stimulated with p286. The peak stimulation index (SI),
as determined by 3[H]thymidine incorporation, was 17
for lymph node cells, and occurred at the 10  g/ml pep-
tide dose (Fig. 4 A). G286 T cells also responded to
GAD65 protein, stimulation index   7 (unpublished
data). When CD4  T cells from G286 mice were sorted
into tetramer-positive and tetramer-negative popula-
tions, only the tetramer-positive cells showed significant
proliferation (Fig. 4 B). No IL-4 or IL-5 was detected in
response to p286 in either the nontransgenic or G286
mice at any dose (unpublished data). Lymph node cells
from G286 mice produced TNF- , IL-2, IFN- , and
IL-10 in response to p286 (Fig. 4 C and unpublished
data). The levels of IFN-  produced were high; in one
experiment, an antigen dose of 15  g/ml elicited 265
ng/ml of IFN-  at 48 h. Lymphocytes from nontrans-
genic littermates produced no detectable IFN- , TNF- ,
IL-2, or IL-10 in response to p286 (unpublished data).
In conclusion, T cells from G286 mice are functional
and respond in vitro to their cognate antigen with pro-
liferation and cytokine production.
In some systems, T cells that are capable of responding
to their antigen in vitro cannot respond to the same an-
tigen in vivo (41, 42). To determine if p286-specific T
cells are capable of being activated in vivo, G286 mice
were immunized with CFA or CFA and p286. Draining
lymph node cells were harvested 60 h after immuniza-
tion. CD4  tetramer  cells from mice immunized with
p286 expressed higher levels of CD44 and lower levels
of CD62L than those isloated from mice which received
CFA alone (Fig. 4 D), suggesting that p286-specific cells
are not tolerant in vivo. To determine if in vivo activa-
tion could induce G286 T cells to induce diabetes, 8–10-
wk-old G286 mice were immunized with IFA and 100
 g p286. CFA was not used because it alone can prevent
diabetes (43, 44). Of six G286 mice followed, none be-
came diabetic.
Figure 2.  Evidence  for expression of
multiple TCRs in G286 mice. (A) Periph-
eral blood lymphocytes from G286 C  / 
(left) G286 C  /  (middle) and NOD
C  /  (right) mice were stained with anti-
bodies for CD4 and V 8 (top) or CD8 and
V 2 (bottom). The percentage of cells in
each quadrant are indicated in each corner
of the plots. (B) Cells from lymph node of a
G286 mouse or thymus of a G286 C  / 
mouse were stained with antibodies for
CD4, CD8, and CD3. Cells were gated on
CD4  or CD8 . Expression of CD3 versus
I-Ag7-286 tetramer is shown. Cells in the
diagonal gate represent cells for which the
p286-specific TCR is the predominant
TCR expressed. Percentage of cells in the
gates drawn are indicated on the plots.486 Glutamic Acid Decarboxylase 65–specific T Cells Delay Diabetes Transfer
T Cells from G286 Mice Do Not Transfer Diabetes but Pro-
tect Against Diabetes Transfer by Splenocytes from Diabetic
NOD Mice. To determine if this p286-specific CD4  T
cell response has a protective role in diabetes pathogenesis,
G286 spleen cells were transferred together with spleen cells
from diabetic NOD females. Splenocytes from diabetic
NOD females transfer diabetes into 80–100% of NOD.scid
recipients within 40 d of transfer (Fig. 5). By contrast, trans-
fer of splenocytes from G286 mice alone does not transfer
diabetes. The addition of G286 splenocytes to diabetogenic
cells results in a significant delay in diabetes transfer (Fig. 5
A). In most of the transfer experiments, even the mice which
received lymphocytes from G286 mice eventually developed
diabetes. This may be because the pathogenic cells from dia-
betic NOD mice divide faster or take longer to die than the
protective G286 cells, allowing the pathogenic cells to over-
whelm the G286 cells over time.
In one experiment, the dose of diabetogenic spleen
cells was reduced to 2   106 and the dose of activated
G286 cells was reduced to 2   105; only 2/6 of mice re-
ceiving both populations developed diabetes compared
with 10/10 mice which received only the diabetogenic
cells (Fig. 5 B). The ability of a lower ratio of G286 cells/
diabetogenic cells to still protect indicates that the delays
in disease progression observed are not due to a dilution
of the diabetogenic cells by T cells with a neutral role in
diabetes pathogenesis.
The delay in diabetes is increased when CD4  cells from
G286 mice are activated (Fig. 5, C and D). CD4  popula-
tions activated using irradiated NOD spleen cells as APCs
with p286 protected longer than those activated with a
nonspecific stimulus such as anti-CD3. Whereas stimulation
with p286 only stimulates p286-specific T cells, anti-CD3
stimulation should stimulate all T cells. The G286 transfer
studies demonstrate that CD4  T cells from G286 mice are
not diabetogenic and are protective against diabetes transfer.
To show that the delays observed are specific to G286,
spleen cells from 8-wk-old G286 and NOD mice were
both activated with anti-CD3 (Fig. 5 E). G286 spleen cells
displayed significantly better protection than NOD spleen
cells. Previous studies show that NOD lymphocytes from
young mice are capable of diabetes protection, but this ca-
pacity diminishes with age (7). This explains the slight de-
lay in diabetes when NOD spleen cells from 8-wk-old
mice are added. Most of the G286 mice used in these trans-
fer experiments were older–an age at which NOD mice do
not normally show protection.
Tetramer-Positive CD4  Cells from G286 Mice Can Delay
Diabetes Transfer. CD4  T cells from G286 mice contain
p286-specific cells as well as T cells of other specificities
(Fig. 2). Therefore, the observed ability of T cells from
G286 mice to delay diabetes transfer could be due to ei-
ther p286-specific T cells or T cells with other specifici-
ties. To study this, lymph node cells from G286 mice
Figure 3.  Incidence of diabetes and insulitis in G286 mice. (A) Diabetes incidence in female G286 (circles, n   6) or NOD littermates (squares, n  
9). (B) Insulitis in 17-wk-old (left) or 30-wk-old (right) female G286 mice. Islets were scored as either no insulitis, periinsulitis, or intrainsulitis. A total of
42 and 160 islets were scored in the 17-wk-old and 30-wk-old mice, respectively. Salivary gland tissue sections from 22-wk-old NOD (C) and 23-wk-
old G286 (D) mice. Original magnification is 40  for the large picture, and the inset (location in large picture indicated by the black box) shows one fo-
cus of infiltrating lymphocytes at an original magnification of 200 .487 Tarbell et al.
were activated with p286 and sorted into CD4  tetramer-
positive and CD4  tetramer-negative fractions. These
populations were added to spleen cells from diabetic
NOD females and transferred to NOD scid mice. The
tetramer positive fraction was able to delay diabetes trans-
fer in all three experiments performed. The effect of tet-
ramer negative cells was mixed, but in two of three ex-
periments, tetramer negative cells did not delay diabetes
transfer (Fig. 6 and unpublished data). Therefore, the de-
lay in diabetes mediated by activated CD4  T cells from
286 transgenic mice is due, at least in part to cells express-
ing GAD65 p286-specific TCR.
CTLA-4 Expression on Activated G286 CD4  Cells Is
Higher Than on Nontransgenic Cells. Expression of the reg-
ulatory molecule CTLA-4 is one possible mechanism by
which CD4  T cells from G286 mice could mediate protec-
tion from diabetes transfer. For example, increased CTLA-4
expression could lead to downmodulation of other patho-
genic cells by inducing TGF-  expression (45, 46). When T
cells were activated with anti-CD3 and anti–CD28-coated
plates, CD4  lymph node cells from G286 mice expressed
higher levels of CTLA-4 than nontransgenic littermates. In
addition, when CD4  T cells from transgenic mice were di-
vided into tetramer positive and tetramer negative subsets,
Figure 4. Activation and cytokine production by lymphocytes from G286 mice. Lymph node cells
from G286 or NOD mice were activated in vitro with the indicated concentration of p286. Proliferation
for total LN cells (A), or purified populations (B) was determined by 3[H]thymidine incorporation. In
B, CD4  p286 tetramer-positive and CD4  p286 tetramer-negative cells were sorted and activated
with 20  g/ml p286 and irradiated NOD spleen cells; 3[H]thymidine was added for the last 16 of a
96 h incubation. Results are expressed as average stimulation index. The average background counts
for the no antigen controls were 1,396 cpm (A) and 58 cpm (B). (C) Expression of IL-2 at 48 h (top),
IFN-  at 62 h (middle), and IL-10 at 48 h (bottom) was determined by ELISA as described in
Methods. (D) T cells expressing p286-specific TCR are activated in vivo by p286 peptide. 5-wk-old
female G286 mice or transgene negative littermates were immunized in the footpad with either
CFA or CFA with 10  g/ml p286. 60 h later, cells from the draining lymph node were harvested.
CD4  gated cells are shown with p286 tetramer-PE (y axis), and either CD44-FITC or CD62L-
FITC (x axis).488 Glutamic Acid Decarboxylase 65–specific T Cells Delay Diabetes Transfer
the tetramer positive subset expressed higher levels of
CTLA-4 (Fig. 7 A). For the plots shown, the mean fluores-
cence intensity (MFI) of CTLA-4 expression was 4.3 for
CD4  cells from the transgene negative mice. For G286
mice, the MFI of CD4  tetramer-negative cells was 5.8, and
for CD4  tetramer-positive cells was 9.0. Furthermore, cells
expressing higher levels of tetramer staining had higher MFI
for CTLA-4 expression; for the 1% of cells with the highest
tetramer staining, the MFI was 12. The ranges of these in-
creases in CTLA-4 expression are similar to those seen when
comparing expression on CD4 CD25  versus CD4 CD25 
cells (47).
Depletion of CD25  Cells Does Not Alter the Protective Ca-
pacity of Cells from G286 Mice. CD4 CD25  cells have
been shown to be protective against autoimmunity in
many systems. As indicated previously, no difference was
observed in the total percentage of CD4 CD25  cells be-
tween G286 and nontransgenic NOD mice. To further
evaluate the role of this population, G286 spleen cells de-
pleted of CD25  cells were compared with whole spleen
cells in their ability to delay diabetes transfer. Depletion of
CD25  cells had no effect on the kinetics of diabetes trans-
fer (Fig. 7 B). Thus, the protective population found
within the CD4  subset from G286 mice is not likely to be
the CD4 CD25  regulatory population, and probably rep-
resents a different type of CD4  cell-mediated protection.
Discussion
Protection Mediated by 286-specific T Cells. Our results
demonstrate that T cells from G286 mice have specific dia-
betes protective capacity. If 286-specific T cells were neu-
tral in their role in diabetes pathogenesis, one would expect
these transgenic mice to develop diabetes mediated by the
residual TCR repertoire, as has been observed with other
NOD TCR transgenics (13, 14). This is especially true
Figure 5.  Lymphocytes from G286
mice delay transfer of diabetes. Transfer
of lymphocytes from recently diabetic
NOD females and from G286 mice
into NODscid females. The following
populations were transferred: (A) 107
diabetic spleen cells (n   8; circles);
or 107 spleen cells from G286 mice
(n   8; squares); or both populations
together (n   8; diamonds). (B) 2  
106 diabetic spleen cells (circles); 2  
106 diabetic spleen cells plus 2   105
peptide activated CD4  G286 cells
(squares). C) 107 diabetic spleen cells
n    9 (circles); 107 diabetic spleen
cells   107 G286 spleen cells n   11
(squares); 107 diabetic spleen cells plus
107 G286 spleen cells activated with
anti-CD3 plus anti-CD28 n     9
(diamonds); 107 anti-CD3 activated
G286 spleen cells (n   4; triangles).
(D) 107 diabetic spleen cells (n   11;
circles); 107 diabetic spleen cells plus
107 CD3-activated G286 spleen cells
(squares); 107 diabetic spleen cells plus
5    106 peptide activated G286
CD4  spleen cells (n   11; diamonds).
(E) 107 diabetic spleen cells (n   15;
circles); 107 diabetic spleen cells plus
107 CD3-activated G286 spleen cells
(n    13; diamonds); 107 diabetic
spleen cells plus 107 CD3-activated
NOD spleen cells (n   9; squares).489 Tarbell et al.
with G286, because the majority of CD4  cells express
TCRs of other specificities. In addition, one can see the
pathogenic potential of the residual repertoire by the pres-
ence of sialitis in these mice; only the T cell infiltrate in the
pancreas is absent. Most important, p286-activated tet-
ramer-positive CD4  T cells can delay diabetes transfer
into NOD scid mice, indicating that p286-specific T cells
are regulatory and not pathogenic.
The mechanism by which activated CD4  T cells from
G286 mice delay diabetes is unknown. The increased ex-
pression of CTLA-4 on p286-specific T cells (Fig. 6 A)
Figure 6.  p286/I-Ag7 tetramer-positive CD4  T cells from G286 mice
delay diabetes transfer. Tetramer-positive and -negative cells were sorted
from G286 lymph node cells which were activated with irradiated NOD
spleen and p286 for 48 h. B220 and CD8 cells were depleted, and the re-
maining cells were stained with p286 tetramer and CD4 (C, left panel).
Gates were set as indicated (C, middle panel), and cells transferred had
purity of 98% for sorted populations. The indicated populations were
transferred to NOD.scid mice in two separate experiments (A and B).
Group sizes are as follows: In A, diabetic spleen cells (n   10), G286
CD4  (n   10), tetramer-high (n   4), tetramer-negative (n   4). In B,
diabetic spleen cells (n   15), tetramer-high (n   8), tetramer-negative
(n   8).
Figure 7.  Potential mechanisms by which G286 T cells delay diabetes
transfer. (A) CTLA-4 expression on CD4  cells activated with anti-CD3
and anti-CD28. Results shown were gated on CD4 . The top panel
shows CTLA-4 expression for nontransgenic (gray) and G286 (white).
Similar results were found in three separate experiments. The bottom
panel shows CD4  cells from 286 mice gated on tetramer-negative (gray)
or -positive (white). (B) The role of CD25  cells in diabetes transfer. The
G286 spleen cell population was incubated with biotinylated anti-CD25
and these cells were depleted using streptavidin magnetic beads (Dynal).
Diabetic spleen (n   13; circles); diabetic spleen positive 286 spleen (n   12;
squares); diabetic spleen plus CD25-negative 286 spleen (n   13; diamonds);
CD25-negative 286 spleen (n   12; triangles).490 Glutamic Acid Decarboxylase 65–specific T Cells Delay Diabetes Transfer
may be one mechanism by which CD4  T cells from G286
mice regulate diabetes pathogenesis. Since NOD mice nor-
mally have lower levels of CTLA-4 as compared with non-
autoimmune strains (48), this increase in expression may
restore the level of CTLA-4 necessary to regulate autoreac-
tive T cell responses. The expression of IL-10 by G286
lymphocytes may also mediate downregulation of patho-
genic cells, as has been shown for Tr1 cells in EAE and
colitis (11, 49). Currently, we are crossing G286 mice to
NOD mice deficient in either CTLA-4 or IL-10 to deter-
mine the role of these proteins in the protection mediated
by p286-specific T cells.
Preliminary evidence suggests that lymphocytes from
G286 mice produce TGF- , which may also be important
for regulation. It is also possible that IFN-  expression may
be important for this diabetes regulation, as was shown for
BCG-mediated diabetes protection (12). Protection is not
likely to be mediated by a shift of T cells to a Th2 pheno-
type, since these cells did not express IL-4 or IL-5. Because
the total number of CD25  cells are not increased in G286
mice, and depletion of CD25  cells does not affect protec-
tion (Fig. 6 B), the protection observed here is not due to
the CD4 CD25  regulatory subset.
T Cell Responses To Insulin and GAD65 and Their Role in
Diabetes Pathogenesis. The ability to block diabetes progres-
sion by tolerance induction to both GAD65 and insulin has
been given as evidence of the pathogenic importance of T
cell responses to these antigens, such tolerance could be the
result of a direct effect on autoreactive T cells through an-
ergy or deletion of a naturally pathogenic response. Alterna-
tively tolerance could arise through stimulation of an insulin
or GAD-specific regulatory response. Such a regulatory re-
sponse could represent a shifting of a pathogenic response to
a protective response, perhaps by a shift in cytokine produc-
tion; or treatment of mice with GAD65 or insulin in a toler-
izing form could be enhancing preexisting regulatory re-
sponses specific for that autoantigen. It is interesting that
some tolerizing protocols administer the antigen in IFA, an
adjuvant often used to enhance immunity (27, 50).
Much is known about T cell responses to these two an-
tigens which indicates their role in diabetes pathogenesis.
First, T cell responses to insulin are more readily found in
the islets and pancreatic lymph node than in the spleen
(51), while most GAD65-specific clones have been isolated
from spleen cells. It is probable that pathogenic responses
would be found at higher frequency at the site of antigen
than in other lymphoid organs. Second, many pathogenic
and protective insulin-specific clones have been isolated
(52), but only one GAD65-specific clone isolated to date is
pathogenic and quite a few are protective (10, 30). Third,
it has recently been shown that a DNA vaccine encoding
many of the major GAD65 epitopes and IL-4 is protective
(53). When similar DNA vaccines are used encoding insu-
lin and IL-4, diabetes onset is accelerated (54). Finally, an
attempt to induce tolerance to GAD65 by systemic expres-
sion of the protein failed. In fact, disease was exacerbated
in the transgenic line which expressed the highest levels of
GAD65 (55). Preliminary studies with a NOD TCR-
transgenic line specific for another epitope of GAD65
show that T cell responses from these mice are not patho-
genic (unpublished data). These results, along with the
phenotype of the p286-specific TCR transgenic described
here, raise the possibility that GAD65-specific T cell re-
sponses may display a more regulatory phenotype in NOD
mice, whereas insulin-specific T cell responses may be
more pathogenic. Pathogenic responses that develop later
may overwhelm these early protective responses resulting
in   cell destruction and diabetes. Of course, this protec-
tive phenotype may not be representative of all GAD65-
specific T cell responses.
Autoimmunity and Expression of Multiple TCR-  Chains.
In G286 mice, the staining pattern of CD3 versus tetramer
(Fig. 2 B) suggests that dual-specificity T cells are present at
a high frequency. Allelic exclusion of the TCR-  chain lo-
cus is not nearly as complete as for TCR-  chain; it has
been estimated that between 10–30% of peripheral T cells
express more than one   chain on the cell surface (56, 57).
Expression of two specificities has been proposed as a possi-
ble explanation of how nontolerant autoreactive T cells
survive selection to populate the periphery (58, 59), and
expression of a second TCR has been shown to rescue a
self-specific TCR from negative selection (37). This is con-
sistent with results obtained comparing selection of p286-
specific T cells in NOD and NOD C  /  mice, which
show that very few T cells expressing only the p286-spe-
cific TCR survive thymic selection (Fig. 2 A). In other sys-
tems, similar cells with more than one TCR expressed are
hyporesponsive (39). The lower expression of the autore-
active TCR that allows the T cell to survive selection may
also prevent peripheral pathogenicity. It has been proposed
that T cells on the border of avidity necessary for negative
selection undergo “altered negative selection” which re-
sults in a suppressor population (60).
In conclusion, a TCR transgenic mouse line specific for
a known   cell autoantigen, GAD65, is protective and not
diabetogenic. Determining the mechanism by which T
cells from G286 mice protect may identify targets for im-
munomodulatory therapy. In addition, these results add to
the accumulating evidence that many GAD65-specific re-
sponses may be protective and not pathogenic in diabetes.
In the design of antigen-specific immunotherapy, this
knowledge will be critical in deciding whether to manipu-
late the immune response for a particular antigen toward
amplification of a preexisting protective response, or to-
ward dampening or modulation of a pathogenic response.
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